Exploiting antibiotics to understand the ribosome and translation
利用抗生素来了解核糖体和翻译
基本信息
- 批准号:10366000
- 负责人:
- 金额:$ 36.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:Anti-Bacterial AgentsAntibiotic ResistanceAntibioticsAreaBacterial GenesBasic ScienceBindingBiomedical EngineeringCellsClinicalCodeEngineeringEvolutionFree RibosomeGene Expression RegulationGenesGenomeGrowthHybridsInitiator CodonKnowledgeLaboratoriesMedicineOrganismPenetrancePeptidesPharmaceutical PreparationsPhysiologicalPlayProductionProtein BiosynthesisProtein Synthesis InhibitorsProteinsRNARNA, Ribosomal, 23SRegulationResearchRibosomal RNARibosomesRoleSpecificityTestingTranslation InitiationTranslationsbaseexperimental studyfrontiergene productgenome-wideinducible gene expressioninhibitorinsightoperationresearch studyresistance generesistance mechanismribosome profilingsynergismtooltrait
项目摘要
The ribosome plays the key role in protein synthesis and is one of the main targets for antibiotics that
inhibit the growth of bacterial cells. Several key aspects of the functions of the ribosome are not fully
understood and antibiotics could play a critical role in gaining insights into unknown facets of translation.
Our laboratory has been on the forefront of antibiotics research and studies of the functional role of
ribosomal RNA (rRNA). We have elucidated the binding modes and mechanisms of action of a number of
major classes of antibiotics. On the basis of our findings we have proposed the new concept of context- and
protein-specific action of several types of protein synthesis inhibitors. We have also unveiled the operations of
several resistance mechanisms and revealed the principles of regulation of expression of inducible antibiotic
resistance genes. In parallel with our studies of antibiotics, we have advanced the field of ribosome
engineering having constructed the first ribosome with inseparable subunits based on a hybrid of 16S-23S
rRNA, opening new experimental venues for basic research and bioengineering.
Building upon our expertise in antibiotics, gene regulation and ribosome engineering, we will now
advance these areas to principally new frontiers. Our future research will proceed in three main directions: 1)
We will dedicate our effort to advancing the concept of context-specificity of bacterial ribosomal inhibitors to
become applicable to the eukaryotic ribosome. By using ribosome engineering, structural analysis and
genome-wide tests, we will identify compounds capable of binding in the nascent peptide exit tunnel of the
eukaryotic ribosome and interfering with production of a subset of proteins. 2) Our antibiotic-enforced ribosome
profiling experiments led to an unexpected and exciting finding of internal translation initiation inside a number
of bacterial genes. We will analyze the physiological significance of internal initiation, test the production of the
`alternative' gene products, study the regulation of expression of the genes from two different start codons and
explore the evolutionary penetrance of this phenomenon. 3) The ribosome is believed to have originated in the
pre-protein RNA World. However, all the previous attempts to demonstrate the ability of protein-free rRNA to
catalyze peptide bond formation have been unsuccessful. We will use the synergy between ribosome
engineering and antibiotic studies to generate catalytically active rRNA core. Altogether, the proposed
directions of research should significantly advance the use of antibiotics as medicines and as tools for
exploring ribosome functions in protein synthesis and translation regulation. We will use the knowledge of
antibiotic action to expand our understanding of genome plasticity and gene coding and illuminate the critical
questions of the ribosome origin and evolution.
核糖体在蛋白质合成中起关键作用,是抗生素的主要靶标之一
抑制细菌细胞的生长。核糖体功能的几个关键方面不是完全
理解和抗生素可能在洞悉翻译方面的洞察力中发挥关键作用。
我们的实验室一直处于抗生素研究的最前沿,并研究了
核糖体RNA(rRNA)。我们已经阐明了许多许多人的结合模式和作用机制
抗生素的主要类别。根据我们的发现,我们提出了上下文和上下文的新概念
几种类型的蛋白质合成抑制剂的蛋白质特异性作用。我们还揭露了
几种电阻机制,揭示了诱导抗生素表达的调节原理
抗性基因。与我们的抗生素研究同时,我们已经推进了核糖体领域
工程学以基于16S-23S的混合体构建了第一个核糖体,该核糖体具有不可分割的亚基
RRNA,开设了基础研究和生物工程的新实验场所。
在我们在抗生素,基因调节和核糖体工程方面的专业知识的基础上,我们现在将
将这些区域推向主要是新的边界。我们未来的研究将以三个主要方向进行:1)
我们将致力于推进细菌核糖体抑制剂的上下文特异性概念
变得适用于真核核糖体。通过使用核糖体工程,结构分析和
全基因组测试,我们将确定能够结合新生肽出口隧道的化合物
真核生物核糖体并干扰蛋白质的子集。 2)我们的抗生素加强核糖体
分析实验导致了一个数字内部的内部翻译启动的意外而令人兴奋的发现
细菌基因。我们将分析内部启动的生理意义,测试生产
“替代”基因产物,研究来自两个不同起始密码子的基因表达的调节,
探索这种现象的进化渗透率。 3)核糖体被认为起源于
蛋白质RNA世界。但是,以前所有试图证明无蛋白质rRNA的能力
催化肽键的形成不成功。我们将使用核糖体之间的协同作用
工程和抗生素研究以产生催化活性的rRNA核心。总共提议
研究方向应大大提高使用抗生素作为药物的使用和作为工具
探索蛋白质合成和翻译调节中的核糖体功能。我们将使用知识
抗生素作用,以扩大我们对基因组可塑性和基因编码的理解并阐明关键
核糖体来源和进化的问题。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALEXANDER S MANKIN其他文献
ALEXANDER S MANKIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALEXANDER S MANKIN', 18)}}的其他基金
Advancing ribosome-targeting antibacterial peptides with a unique mechanism of action
以独特的作用机制推进核糖体靶向抗菌肽
- 批准号:
10443921 - 财政年份:2022
- 资助金额:
$ 36.36万 - 项目类别:
Advancing ribosome-targeting antibacterial peptides with a unique mechanism of action
以独特的作用机制推进核糖体靶向抗菌肽
- 批准号:
10569098 - 财政年份:2022
- 资助金额:
$ 36.36万 - 项目类别:
Advancing ribosome-targeting antibacterial peptides with a unique mechanism of action
以独特的作用机制推进核糖体靶向抗菌肽
- 批准号:
10436039 - 财政年份:2021
- 资助金额:
$ 36.36万 - 项目类别:
Equipment Supplement Request for Purchasing Amersham Typhoon RGB Phosphorimager (for R35GM127134)
购买 Amersham Typhoon RGB 荧光成像仪(适用于 R35GM127134)的设备补充申请
- 批准号:
10386084 - 财政年份:2018
- 资助金额:
$ 36.36万 - 项目类别:
Exploiting antibiotics to understand the ribosome and translation
利用抗生素来了解核糖体和翻译
- 批准号:
9897557 - 财政年份:2018
- 资助金额:
$ 36.36万 - 项目类别:
Context-specific action of antibiotics targeting the catalytic center of the bacterial ribosome
针对细菌核糖体催化中心的抗生素的特定作用
- 批准号:
9158354 - 财政年份:2016
- 资助金额:
$ 36.36万 - 项目类别:
Context-specific action of antibiotics targeting the catalytic center of the bacterial ribosome
针对细菌核糖体催化中心的抗生素的特定作用
- 批准号:
9332339 - 财政年份:2016
- 资助金额:
$ 36.36万 - 项目类别:
Molecular mechanisms of action of macrolide antibiotics
大环内酯类抗生素的分子作用机制
- 批准号:
8482422 - 财政年份:2013
- 资助金额:
$ 36.36万 - 项目类别:
Molecular mechanisms of action of macrolide antibiotics
大环内酯类抗生素的分子作用机制
- 批准号:
8640960 - 财政年份:2013
- 资助金额:
$ 36.36万 - 项目类别:
Programmed translation arrest controlled by nascent peptides and antibiotics
由新生肽和抗生素控制的程序化翻译停滞
- 批准号:
8917273 - 财政年份:2012
- 资助金额:
$ 36.36万 - 项目类别:
相似国自然基金
基于高通量测序和培养组学的伴侣动物-人抗生素抗性基因分布特征及传播研究
- 批准号:82373646
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
手性酰胺类农药污染的农业土壤中抗生素抗性基因传播扩散的对映选择性机制
- 批准号:42377238
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
猪粪水热炭对红壤-蔬菜系统中抗生素抗性基因的风险控制及其机理
- 批准号:42307038
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
蚯蚓-菌根协同消减抗生素抗性基因的微生物驱动机制
- 批准号:32301448
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
生物炭对厌氧膜生物反应器抑制畜禽养殖废水中抗生素抗性基因的调控作用和机制
- 批准号:52300210
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of Targeted Antipseudomonal Bactericidal Prodrugs
靶向抗假单胞菌杀菌前药的开发
- 批准号:
10678074 - 财政年份:2023
- 资助金额:
$ 36.36万 - 项目类别:
Disrupting Dogma: Investigating LPS Biosynthesis Inhibition as an Alternative Mechanism of Action of Aminoglycoside Antibiotics
颠覆教条:研究 LPS 生物合成抑制作为氨基糖苷类抗生素的替代作用机制
- 批准号:
10653587 - 财政年份:2023
- 资助金额:
$ 36.36万 - 项目类别:
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis
噻唑啉-吡啶酮化合物作为结核病新药
- 批准号:
10698829 - 财政年份:2023
- 资助金额:
$ 36.36万 - 项目类别:
Infection-Dependent Vulnerabilities of Gram-negative Bacterial Pathogens
革兰氏阴性细菌病原体的感染依赖性脆弱性
- 批准号:
10592676 - 财政年份:2023
- 资助金额:
$ 36.36万 - 项目类别:
Brewing anti-toxin drugs using probiotic yeast
利用益生菌酵母酿造抗毒素药物
- 批准号:
10687670 - 财政年份:2023
- 资助金额:
$ 36.36万 - 项目类别: